The Clinical Utility of Combinatorial Pharmacogenomic Testing for Patients with Depression: A Meta-Analysis
Lisa Brown, Oliver Vranjkovic, James Li, Kunbo Yu, Talal Al Habbab, Holly L. Johnson, Krystal Brown, Michael Jablonski, Bryan Dechairo
Abstract
Aim: To perform a meta-analysis of prospective, two-arm studies examining the clinical utility of using the combinatorial pharmacogenomic test, GeneSight Psychotropic, to inform treatment decisions for patients with major depressive disorder (MDD). Patients & methods: The pooled mean effect of symptom improvement and pooled relative risk ratio (RR) of response and remission were calculated using a random effect model. Results: Overall, 1556 patients were included from four studies, with outcomes evaluated at week 8 or week 10. Patient outcomes were significantly improved for patients with MDD whose care was guided by the combinatorial pharmacogenomic test results compared with unguided care (symptom improvement Δ = 10.08%, 95% CI: 1.67–18.50; p = 0.019; response RR = 1.40, 95% CI: 1.17–1.67; p < 0.001; remission RR = 1.49, 95% CI: 1.17–1.89; p = 0.001). Conclusion: GeneSight Psychotropic guided care improves outcomes among patients with MDD.